The New England Journal of Medicine published research this week describing a blood test for mesothelioma, a rare form of cancer that is often caused by exposure to asbestos. The assay measures plasma levels of fibulin-3 which were found to be significantly increased in patients with the disease. The protein was also found to be elevated in lung fluid. Measuring fibulin-3 levels resulted in a test that had 96.7% sensitivity for correctly identifying cancer patients and a specificity of 95.5%. Future research needs to be done to determine whether fibulin-3 will be useful as an early detection marker or one that could track disease progression.